A number of laboratory studies have confirmed the efficacy of opioid medication in reducing pain generated by a number of psychophysical modalities. However, one implicit assumption of clinical and experimental pain testing of analgesics is that the analgesic response is stable and will be comparable across repeated administrations. In the current study, the repeatability of opioid analgesia was assessed in a randomized, double-blinded study using 3 psychophysical pain modalities (e.g., thermal, pressure, and ischemic) over 4 medication sessions (2 with active drug, 2 with placebo). Psychophysical responses were evaluated before and after intravenous administration of either morphine (0.08 mg/kg; n = 52) or pentazocine (0.5 mg/kg; n = 49). To determine the ability of a drug to reduce pain, 4 analytic methods (i.e., absolute change, percent change, ratio, and residualized change scores) were calculated to generate separate analgesic index scores for each measure and drug condition. All analgesic index scores demonstrated a greater analgesic response compared to saline for both medications, but stability (i.e., test-retest correlations) of the opioid analgesic indices depended on the pain measurement. Ischemic pain outcomes were moderately stable across sessions for both opioid medications; however, heat and pressure analgesic index scores were moderately stable for only morphine and pentazocine, respectively. Finally, within stimulus modalities, analgesic index scores were highly correlated with each other, suggesting that the different methods for computing analgesic responses provided comparable results. These results suggest that analgesic measures are able to distinguish between active drugs. In addition, analgesic responses to morphine and pentazocine demonstrate at least moderate reliability.
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Introduction
The management of pain in clinical settings continues to be a challenge. The cost of pain management is well established, with a tremendous loss in productivity, decreased quality of life, and increasing costs to the health care system [33] . Currently, several strategies are used to manage acute pain, including the utilization of opioid analgesics [48, 58] , which exert their effects by activation of opioid receptors [63] in areas involved in pain processing [28, 64] . Analgesic efficacy, or the ability of an opioid analgesic to reduce pain, has been examined in experimental models of pain, which control confounding variables that can affect outcomes in clinical studies (e.g., interindividual variability in disease severity and clinical symptoms). Experimental modalities also allow concurrent assessment of opioid effects on diverse pain modalities activating different mechanisms [56] . In these studies, 2 opioid analgesics have been shown to reduce experimental pain sensitivity across multiple stimulus modalities, including morphine, a l-agonist [21, 38, 49, 50] , and pentazocine, a mixed action agonistantagonist [18, 22, 49] .
The most common analytical method for computing analgesic efficacy in experimental pain studies is the use of absolute change scores [14,21,22,34,52]. These scores are commonly derived by calculating the differences between the experimental pain outcomes collected during the predrug and postdrug periods. However, several questions have been raised about the reliability of these scores [4,5,9], particularly in studies designed for repeated assessment of pretest/posttest paradigms. Despite being measured with the same methods (e.g., thresholds, ratings), difference scores can be
